{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:12:53Z","timestamp":1793686373469,"version":"4.5.1"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of the Review<\/jats:title>\n                    <jats:p>We aimed to summarize the pathogenic role of IL-6 in atherothrombosis and myocardial infarction (MI), with focus on novel pathogenic mechanisms and current IL-6 targeted therapy in clinical cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>IL-6 plays a major role in the pathogenesis of cardiovascular disease interacting with aging- and metabolic-driven inflammation, two conditions with overlapping molecular mechanisms. A novel pathogenic mechanism in cardiovascular disease (CVD) is the interaction between IL-6 and clonal hematopoiesis of indeterminate potential, CHIP, that involve the ten-eleven translocation-2 gene, a molecule with role in epigenetics. Recent studies showed reduced inflammation, a reduction in Lp (a) and inhibitory effects on platelets by anti-IL-6 (ziltivekimab) therapy in patients at risk for CVD. Anti-IL-6 receptor therapy (tocilizumab) showed reduced inflammation and improved myocardial function in MI patients, involving reduced degranulation in neutrophils and modulation of monocytes. Studies with clinical endpoints are still lacking and there also a need for developing therapy that selectively block the harmful IL-6 trans-signaling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>IL-6 plays an important and many-faceted role in atherothrombosis including MI and ischemic stroke, and the IL-6 system represent a promising but still evolving therapeutic approach. A comprehensive understanding of the complexity of IL-6 signaling is needed to improve such treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11883-025-01387-8","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:14:37Z","timestamp":1768551277000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Role of Interleukin-6 in Atherothrombosis and Myocardial Infarction"],"prefix":"10.1007","volume":"28","author":[{"given":"Camilla","family":"Huse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Gregersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredric A.","family":"Holme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thor","family":"Ueland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Skjelland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Hege","family":"Aamodt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuva B.","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l","family":"Aukrust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"Halvorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"issue":"3","key":"1387_CR1","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/eurjpc\/zwac285","volume":"30","author":"Y Li","year":"2023","unstructured":"Li Y, Cao GY, Jing WZ, Liu J, Liu M. Global trends and regional differences in incidence and mortality of cardiovascular disease, 1990\u20132019: findings from 2019 global burden of disease study. Eur J Prev Cardiol. 2023;30(3):276\u201386.","journal-title":"Eur J Prev Cardiol"},{"issue":"8","key":"1387_CR2","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1161\/CIR.0000000000001303","volume":"151","author":"SS Martin","year":"2025","unstructured":"Martin SS, Aday AW, Allen NB, Almarzooq ZI, Anderson CAM, Arora P, et al. 2025 heart disease and stroke statistics: A report of US and global data from the American heart association. Circulation. 2025;151(8):e41\u2013660.","journal-title":"Circulation"},{"issue":"5","key":"1387_CR3","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1161\/ATVBAHA.124.319397","volume":"44","author":"Z Mallat","year":"2024","unstructured":"Mallat Z, Tedgui A. Century of milestones and breakthroughs related to the immune mechanisms of atherosclerosis. Arterioscler Thromb Vasc Biol. 2024;44(5):1002\u20136.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"1387_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1161\/01.ATV.6.2.131","volume":"6","author":"L Jonasson","year":"1986","unstructured":"Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis. 1986;6(2):131\u20138.","journal-title":"Arteriosclerosis"},{"issue":"16","key":"1387_CR5","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMra043430","volume":"352","author":"GK Hansson","year":"2005","unstructured":"Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685\u201395.","journal-title":"N Engl J Med"},{"issue":"25","key":"1387_CR6","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1016\/j.jacc.2018.06.082","volume":"72","author":"PM Ridker","year":"2018","unstructured":"Ridker PM. Clinician\u2019s guide to reducing inflammation to reduce atherothrombotic risk: JACC review topic of the week. J Am Coll Cardiol. 2018;72(25):3320\u201331.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"1387_CR7","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/eurheartj\/ehw024","volume":"37","author":"PM Ridker","year":"2016","unstructured":"Ridker PM. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J. 2016;37(22):1720\u20132.","journal-title":"Eur Heart J"},{"issue":"12","key":"1387_CR8","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119\u201331.","journal-title":"N Engl J Med"},{"issue":"38","key":"1387_CR9","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","volume":"39","author":"PM Ridker","year":"2018","unstructured":"Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018;39(38):3499\u2013507.","journal-title":"Eur Heart J"},{"issue":"11","key":"1387_CR10","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","volume":"128","author":"PM Ridker","year":"2021","unstructured":"Ridker PM, Rane M. Interleukin-6 signaling and anti-Interleukin-6 therapeutics in cardiovascular disease. Circ Res. 2021;128(11):1728\u201346.","journal-title":"Circ Res"},{"key":"1387_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1255533","volume":"14","author":"E Grebenciucova","year":"2023","unstructured":"Grebenciucova E, VanHaerents S. Interleukin 6: at the interface of human health and disease. Front Immunol. 2023;14:1255533.","journal-title":"Front Immunol"},{"issue":"15","key":"1387_CR12","doi-asserted-by":"publisher","first-page":"9090","DOI":"10.1073\/pnas.1531903100","volume":"100","author":"JK Kiecolt-Glaser","year":"2003","unstructured":"Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, Atkinson C, Malarkey WB, Glaser R. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc Natl Acad Sci U S A. 2003;100(15):9090\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1387_CR13","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1161\/01.CIR.91.5.1520","volume":"91","author":"K Yamauchi-Takihara","year":"1995","unstructured":"Yamauchi-Takihara K, Ihara Y, Ogata A, Yoshizaki K, Azuma J, Kishimoto T. Hypoxic stress induces cardiac myocyte-derived interleukin-6. Circulation. 1995;91(5):1520\u20134.","journal-title":"Circulation"},{"issue":"4","key":"1387_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1006\/cyto.2002.1033","volume":"18","author":"C Ancey","year":"2002","unstructured":"Ancey C, Corbi P, Froger J, Delwail A, Wijdenes J, Gascan H, et al. Secretion of IL-6, IL-11 and LIF by human cardiomyocytes in primary culture. Cytokine. 2002;18(4):199\u2013205.","journal-title":"Cytokine"},{"issue":"9","key":"1387_CR15","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.7150\/ijbs.4679","volume":"8","author":"M Erta","year":"2012","unstructured":"Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci. 2012;8(9):1254\u201366.","journal-title":"Int J Biol Sci"},{"key":"1387_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109130","volume":"111","author":"M Aliyu","year":"2022","unstructured":"Aliyu M, Zohora FT, Anka AU, Ali K, Maleknia S, Saffarioun M, et al. Interleukin-6 cytokine: an overview of the immune regulation, immune dysregulation, and therapeutic approach. Int Immunopharmacol. 2022;111:109130.","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"1387_CR17","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016295","volume":"6","author":"T Tanaka","year":"2014","unstructured":"Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1387_CR18","doi-asserted-by":"publisher","first-page":"641734","DOI":"10.3389\/fmolb.2021.641734","volume":"8","author":"P Villar-Fincheira","year":"2021","unstructured":"Villar-Fincheira P, Sanhueza-Olivares F, Norambuena-Soto I, Cancino-Arenas N, Hernandez-Vargas F, Troncoso R, et al. Role of Interleukin-6 in vascular health and disease. Front Mol Biosci. 2021;8:641734.","journal-title":"Front Mol Biosci"},{"issue":"6","key":"1387_CR19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","volume":"16","author":"EH Choy","year":"2020","unstructured":"Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020;16(6):335\u201345.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"1387_CR20","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.cmet.2014.05.009","volume":"19","author":"AJ Covarrubias","year":"2014","unstructured":"Covarrubias AJ, Horng T. IL-6 strikes a balance in metabolic inflammation. Cell Metab. 2014;19(6):898\u20139.","journal-title":"Cell Metab"},{"key":"1387_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1330386","volume":"15","author":"A Tylutka","year":"2024","unstructured":"Tylutka A, Walas \u0141, Zembron-Lacny A. Level of IL-6, TNF, and IL-1\u03b2 and age-related diseases: a systematic review and meta-analysis. Front Immunol. 2024;15:1330386.","journal-title":"Front Immunol"},{"key":"1387_CR22","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.bbi.2024.06.014","volume":"120","author":"Z Zhao","year":"2024","unstructured":"Zhao Z, Zhang J, Wu Y, Xie M, Tao S, Lv Q, et al. Plasma IL-6 levels and their association with brain health and dementia risk: A population-based cohort study. Brain Behav Immun. 2024;120:430\u20138.","journal-title":"Brain Behav Immun"},{"issue":"16","key":"1387_CR23","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/eurjpc\/zwad197","volume":"30","author":"X Jia","year":"2023","unstructured":"Jia X, Buckley L, Sun C, Al Rifai M, Yu B, Nambi V, et al. Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults: Atherosclerosis Risk in Communities study. Eur J Prev Cardiol. 2023;30(16):1731\u201340.","journal-title":"Eur J Prev Cardiol"},{"key":"1387_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00586","volume":"9","author":"IM Rea","year":"2018","unstructured":"Rea IM, Gibson DS, McGilligan V, McNerlan SE, Alexander HD, Ross OA. Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines. Front Immunol. 2018;9:586.","journal-title":"Front Immunol"},{"key":"1387_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2018.09.002","volume":"55","author":"BE Jones","year":"2018","unstructured":"Jones BE, Maerz MD, Buckner JH. IL-6: a cytokine at the crossroads of autoimmunity. Curr Opin Immunol. 2018;55:9\u201314.","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"1387_CR26","doi-asserted-by":"publisher","first-page":"e1093722","DOI":"10.1080\/2162402X.2015.1093722","volume":"5","author":"BE Lippitz","year":"2016","unstructured":"Lippitz BE, Harris RA. Cytokine patterns in cancer patients: a review of the correlation between Interleukin 6 and prognosis. Oncoimmunology. 2016;5(5):e1093722.","journal-title":"Oncoimmunology"},{"issue":"1","key":"1387_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17942-7","volume":"11","author":"S Valletta","year":"2020","unstructured":"Valletta S, Thomas A, Meng Y, Ren X, Drissen R, Seng\u00fcl H, et al. Micro-environmental sensing by bone marrow stroma identifies IL-6 and TGF\u03b21 as regulators of hematopoietic ageing. Nat Commun. 2020;11(1):4075.","journal-title":"Nat Commun"},{"issue":"13","key":"1387_CR28","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.15252\/embj.201488856","volume":"33","author":"JJ Fuster","year":"2014","unstructured":"Fuster JJ, Walsh K. The good, the bad, and the ugly of interleukin-6 signaling. EMBO J. 2014;33(13):1425\u20137.","journal-title":"EMBO J"},{"issue":"Suppl 2","key":"1387_CR29","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1186\/ar1917","volume":"8","author":"C Gabay","year":"2006","unstructured":"Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther. 2006;8(Suppl 2):S3.","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"1387_CR30","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41574-018-0059-4","volume":"14","author":"C Franceschi","year":"2018","unstructured":"Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14(10):576\u201390.","journal-title":"Nat Rev Endocrinol"},{"key":"1387_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/genes13112074","author":"L Qu","year":"2022","unstructured":"Qu L, Matz AJ, Karlinsey K, Cao Z, Vella AT, Zhou B. Macrophages at the crossroad of meta-inflammation and inflammaging. Genes. 2022. https:\/\/doi.org\/10.3390\/genes13112074.","journal-title":"Genes"},{"issue":"2","key":"1387_CR32","doi-asserted-by":"publisher","first-page":"E433","DOI":"10.1152\/ajpendo.00074.2003","volume":"285","author":"A Steensberg","year":"2003","unstructured":"Steensberg A, Fischer CP, Keller C, M\u00f8ller K, Pedersen BK. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab. 2003;285(2):E433\u20137.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"1387_CR33","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jhep.2018.10.023","volume":"70","author":"B Gao","year":"2019","unstructured":"Gao B, Ahmad MF, Nagy LE, Tsukamoto H. Inflammatory pathways in alcoholic steatohepatitis. J Hepatol. 2019;70(2):249\u201359.","journal-title":"J Hepatol"},{"issue":"1","key":"1387_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00527-1","volume":"13","author":"MJ Wang","year":"2024","unstructured":"Wang MJ, Zhang HL, Chen F, Guo XJ, Liu QG, Hou J. The double-edged effects of IL-6 in liver regeneration, aging, inflammation, and diseases. Exp Hematol Oncol. 2024;13(1):62.","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"1387_CR35","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.immuni.2019.03.026","volume":"50","author":"S Kang","year":"2019","unstructured":"Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting interleukin-6 signaling in clinic. Immunity. 2019;50(4):1007\u201323.","journal-title":"Immunity"},{"issue":"3","key":"1387_CR36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000505099","volume":"98","author":"P Uciechowski","year":"2020","unstructured":"Uciechowski P, Dempke WCM. Interleukin-6: a masterplayer in the cytokine network. Oncology. 2020;98(3):131\u20137.","journal-title":"Oncology"},{"issue":"1","key":"1387_CR37","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1046\/j.1432-1327.2001.01867.x","volume":"268","author":"T Jostock","year":"2001","unstructured":"Jostock T, M\u00fcllberg J, \u00d6zbek S, Atreya R, Blinn G, Voltz N, et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem. 2001;268(1):160\u20137.","journal-title":"Eur J Biochem"},{"issue":"1","key":"1387_CR38","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/ni.3632","volume":"18","author":"S Heink","year":"2017","unstructured":"Heink S, Yogev N, Garbers C, Herwerth M, Aly L, Gasperi C, et al. Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells. Nat Immunol. 2017;18(1):74\u201385.","journal-title":"Nat Immunol"},{"issue":"7","key":"1387_CR39","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.amjcard.2006.04.034","volume":"98","author":"MM Ramadan","year":"2006","unstructured":"Ramadan MM, Kodama M, Mitsuma W, Ito M, Kashimura T, Ikrar T, et al. Impact of percutaneous coronary intervention on the levels of interleukin-6 and C-reactive protein in the coronary circulation of subjects with coronary artery disease. Am J Cardiol. 2006;98(7):915\u20137.","journal-title":"Am J Cardiol"},{"issue":"1","key":"1387_CR40","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12964-019-0356-0","volume":"17","author":"H Reeh","year":"2019","unstructured":"Reeh H, Rudolph N, Billing U, Christen H, Streif S, Bullinger E, et al. Response to IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor \u03b1 to gp130 expression: fusing experimental insights and dynamic modelling. Cell Commun Signal. 2019;17(1):46.","journal-title":"Cell Commun Signal"},{"key":"1387_CR41","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3389\/fphys.2019.00500","volume":"10","author":"V Moresi","year":"2019","unstructured":"Moresi V, Adamo S, Berghella L. The JAK\/STAT pathway in skeletal muscle pathophysiology. Front Physiol. 2019;10:500.","journal-title":"Front Physiol"},{"key":"1387_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155750","volume":"149","author":"KY Fung","year":"2022","unstructured":"Fung KY, Louis C, Metcalfe RD, Kosasih CC, Wicks IP, Griffin MDW, et al. Emerging roles for IL-11 in inflammatory diseases. Cytokine. 2022;149:155750.","journal-title":"Cytokine"},{"issue":"7","key":"1387_CR43","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1053\/j.gastro.2021.02.062","volume":"160","author":"S Schreiber","year":"2021","unstructured":"Schreiber S, Aden K, Bernardes JP, Conrad C, Tran F, H\u00f6per H, et al. Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in patients with active inflammatory bowel disease. Gastroenterology. 2021;160(7):2354\u2013e6611.","journal-title":"Gastroenterology"},{"issue":"10","key":"1387_CR44","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","volume":"23","author":"S Rose-John","year":"2023","unstructured":"Rose-John S, Jenkins BJ, Garbers C, Moll JM, Scheller J. Targeting IL-6 trans-signalling: past, present and future prospects. Nat Rev Immunol. 2023;23(10):666\u201381.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"1387_CR45","first-page":"431","volume":"6","author":"MJ George","year":"2021","unstructured":"George MJ, Jasmin NH, Cummings VT, Richard-Loendt A, Launchbury F, Woollard K, et al. Selective Interleukin-6 trans-signaling blockade is more effective than panantagonism in reperfused myocardial infarction. JACC: Basic to Translational Science. 2021;6(5):431\u201343.","journal-title":"JACC: Basic to Translational Science"},{"issue":"1","key":"1387_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-024-01259-7","volume":"27","author":"NN Mehta","year":"2024","unstructured":"Mehta NN, deGoma E, Shapiro MD. IL-6 and cardiovascular risk: a narrative review. Curr Atheroscler Rep. 2024;27(1):12.","journal-title":"Curr Atheroscler Rep"},{"key":"1387_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd11070206","author":"N Katkenov","year":"2024","unstructured":"Katkenov N, Mukhatayev Z, Kozhakhmetov S, Sailybayeva A, Bekbossynova M, Kushugulova A. Systematic review on the role of IL-6 and IL-1\u03b2 in cardiovascular diseases. J Cardiovasc Dev Dis. 2024. https:\/\/doi.org\/10.3390\/jcdd11070206.","journal-title":"J Cardiovasc Dev Dis"},{"key":"1387_CR48","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2021\/e2690","volume":"76","author":"C Yang","year":"2021","unstructured":"Yang C, Deng Z, Li J, Ren Z, Liu F. Meta-analysis of the relationship between interleukin-6 levels and the prognosis and severity of acute coronary syndrome. Clinics (Sao Paulo). 2021;76:e2690.","journal-title":"Clinics (Sao Paulo)"},{"key":"1387_CR49","doi-asserted-by":"publisher","first-page":"818890","DOI":"10.3389\/fcvm.2022.818890","volume":"9","author":"Y Feng","year":"2022","unstructured":"Feng Y, Ye D, Wang Z, Pan H, Lu X, Wang M, et al. The role of Interleukin-6 family members in cardiovascular diseases. Front Cardiovasc Med. 2022;9:818890.","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"1387_CR50","doi-asserted-by":"publisher","first-page":"101063","DOI":"10.1016\/j.jacadv.2024.101063","volume":"3","author":"MS Khan","year":"2024","unstructured":"Khan MS, Talha KM, Maqsood MH, Rymer JA, Borlaug BA, Docherty KF, et al. Interleukin-6 and cardiovascular events in healthy adults: MESA. JACC Adv. 2024;3(8):101063.","journal-title":"JACC Adv"},{"issue":"4","key":"1387_CR51","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oeae047","volume":"4","author":"DFJ Ketelhuth","year":"2024","unstructured":"Ketelhuth DFJ, B\u00e4ck M. Myeloid-specific interleukin-6 response: from vascular effects to the potential for novel personalized medicines. Eur Heart J Open. 2024;4(4):oeae047.","journal-title":"Eur Heart J Open"},{"issue":"11","key":"1387_CR52","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aau6986","volume":"4","author":"L Wang","year":"2018","unstructured":"Wang L, Ozark PA, Smith ER, Zhao Z, Marshall SA, Rendleman EJ, et al. TET2 coactivates gene expression through demethylation of enhancers. Sci Adv. 2018;4(11):eaau6986.","journal-title":"Sci Adv"},{"key":"1387_CR53","doi-asserted-by":"publisher","DOI":"10.1172\/JCI163968","author":"SK Pasupuleti","year":"2023","unstructured":"Pasupuleti SK, Ramdas B, Burns SS, Palam LR, Kanumuri R, Kumar R, et al. Obesity-induced inflammation exacerbates clonal hematopoiesis. J Clin Invest. 2023. https:\/\/doi.org\/10.1172\/JCI163968.","journal-title":"J Clin Invest"},{"issue":"26","key":"1387_CR54","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488\u201398.","journal-title":"N Engl J Med"},{"issue":"2","key":"1387_CR55","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.119.044362","volume":"141","author":"AG Bick","year":"2020","unstructured":"Bick AG, Pirruccello JP, Griffin GK, Gupta N, Gabriel S, Saleheen D, et al. Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis. Circulation. 2020;141(2):124\u201331.","journal-title":"Circulation"},{"issue":"24","key":"1387_CR56","doi-asserted-by":"publisher","first-page":"7471","DOI":"10.1182\/bloodadvances.2023011578","volume":"7","author":"J Woo","year":"2023","unstructured":"Woo J, Lu D, Lewandowski A, Xu H, Serrano P, Healey M, et al. Effects of IL-1\u03b2 Inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial. Blood Adv. 2023;7(24):7471\u201384.","journal-title":"Blood Adv"},{"issue":"2","key":"1387_CR57","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111\u201321.","journal-title":"N Engl J Med"},{"issue":"6327","key":"1387_CR58","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1126\/science.aag1381","volume":"355","author":"JJ Fuster","year":"2017","unstructured":"Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355(6327):842\u20137.","journal-title":"Science"},{"key":"1387_CR59","doi-asserted-by":"publisher","first-page":"5525917","DOI":"10.1155\/2021\/5525917","volume":"2021","author":"J Nordeng","year":"2021","unstructured":"Nordeng J, Schandiz H, Solheim S, \u00c5kra S, Hoffman P, Roald B, et al. The inflammasome signaling pathway is actively regulated and related to myocardial damage in coronary thrombi from patients with STEMI. Mediators Inflamm. 2021;2021:5525917.","journal-title":"Mediators Inflamm"},{"key":"1387_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/cells10010051","author":"WP Lafuse","year":"2020","unstructured":"Lafuse WP, Wozniak DJ, Rajaram MVS. Role of cardiac macrophages on cardiac inflammation, fibrosis and tissue repair. Cells. 2020. https:\/\/doi.org\/10.3390\/cells10010051.","journal-title":"Cells"},{"issue":"Suppl 6A","key":"1387_CR61","doi-asserted-by":"publisher","first-page":"s9","DOI":"10.1016\/j.amjmed.2004.02.006","volume":"116","author":"P Libby","year":"2004","unstructured":"Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med. 2004;116(Suppl 6A):s9\u201316.","journal-title":"Am J Med"},{"issue":"10","key":"1387_CR62","doi-asserted-by":"publisher","first-page":"e1002","DOI":"10.1212\/WNL.0000000000013274","volume":"98","author":"A Papadopoulos","year":"2022","unstructured":"Papadopoulos A, Palaiopanos K, Bj\u00f6rkbacka H, Peters A, de Lemos JA, Seshadri S, et al. Circulating interleukin-6 levels and incident ischemic stroke: a systematic review and meta-analysis of prospective studies. Neurology. 2022;98(10):e1002-12.","journal-title":"Neurology"},{"issue":"2","key":"1387_CR63","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41419-019-1413-8","volume":"10","author":"Y Yang","year":"2019","unstructured":"Yang Y, Wang H, Kouadir M, Song H, Shi F. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis. 2019;10(2):128.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1387_CR64","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jacbts.2021.08.006","volume":"7","author":"MB Olsen","year":"2022","unstructured":"Olsen MB, Gregersen I, Sandanger \u00d8, Yang K, Sokolova M, Halvorsen BE, et al. Targeting the inflammasome in cardiovascular disease. JACC Basic Transl Sci. 2022;7(1):84\u201398.","journal-title":"JACC Basic Transl Sci"},{"key":"1387_CR65","doi-asserted-by":"publisher","first-page":"102985","DOI":"10.1016\/j.ebiom.2020.102985","volume":"60","author":"N Niyonzima","year":"2020","unstructured":"Niyonzima N, Bakke SS, Gregersen I, Holm S, Sandanger \u00d8, Orrem HL, et al. Cholesterol crystals use complement to increase NLRP3 signaling pathways in coronary and carotid atherosclerosis. EBioMedicine. 2020;60:102985.","journal-title":"EBioMedicine"},{"issue":"38","key":"1387_CR66","doi-asserted-by":"publisher","first-page":"25900","DOI":"10.1074\/jbc.M707692200","volume":"283","author":"CM Cahill","year":"2008","unstructured":"Cahill CM, Rogers JT. Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT\/IkappaB kinase alpha pathway targeting activator protein-1. J Biol Chem. 2008;283(38):25900\u201312.","journal-title":"J Biol Chem"},{"issue":"6","key":"1387_CR67","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1182\/blood.V75.6.1305.1305","volume":"75","author":"G Tosato","year":"1990","unstructured":"Tosato G, Jones KD. Interleukin-1 induces interleukin-6 production in peripheral blood monocytes. Blood. 1990;75(6):1305\u201310.","journal-title":"Blood"},{"key":"1387_CR68","doi-asserted-by":"publisher","first-page":"1077290","DOI":"10.3389\/fcvm.2022.1077290","volume":"9","author":"T Li","year":"2022","unstructured":"Li T, Yan Z, Fan Y, Fan X, Li A, Qi Z, et al. Cardiac repair after myocardial infarction: A two-sided role of inflammation-mediated. Front Cardiovasc Med. 2022;9:1077290.","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"1387_CR69","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/eurheartj\/ehad486","volume":"45","author":"MA Matter","year":"2024","unstructured":"Matter MA, Paneni F, Libby P, Frantz S, St\u00e4hli BE, Templin C, et al. Inflammation in acute myocardial infarction: the good, the bad and the ugly. Eur Heart J. 2024;45(2):89\u2013103.","journal-title":"Eur Heart J"},{"issue":"7","key":"1387_CR70","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/cvr\/cvy304","volume":"115","author":"CJ Zuurbier","year":"2019","unstructured":"Zuurbier CJ, Abbate A, Cabrera-Fuentes HA, Cohen MV, Collino M, De Kleijn DPV, et al. Innate immunity as a target for acute cardioprotection. Cardiovasc Res. 2019;115(7):1131\u201342.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"1387_CR71","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0008-6363(01)00434-5","volume":"53","author":"NG Frangogiannis","year":"2002","unstructured":"Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53(1):31\u201347.","journal-title":"Cardiovasc Res"},{"issue":"12","key":"1387_CR72","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1161\/CIRCRESAHA.124.323658","volume":"134","author":"I Hilgendorf","year":"2024","unstructured":"Hilgendorf I, Frantz S, Frangogiannis NG. Repair of the infarcted heart: cellular effectors, molecular mechanisms and therapeutic opportunities. Circ Res. 2024;134(12):1718\u201351.","journal-title":"Circ Res"},{"issue":"1","key":"1387_CR73","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1161\/CIRCRESAHA.111.243162","volume":"110","author":"NG Frangogiannis","year":"2012","unstructured":"Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res. 2012;110(1):159\u201373.","journal-title":"Circ Res"},{"key":"1387_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2019.00140","volume":"6","author":"A Hanna","year":"2019","unstructured":"Hanna A, Frangogiannis NG. The role of the TGF-\u03b2 superfamily in myocardial infarction. Front Cardiovasc Med. 2019;6:140.","journal-title":"Front Cardiovasc Med"},{"key":"1387_CR75","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3389\/fphys.2017.00777","volume":"8","author":"LA Murtha","year":"2017","unstructured":"Murtha LA, Schuliga MJ, Mabotuwana NS, Hardy SA, Waters DW, Burgess JK, et al. The processes and mechanisms of cardiac and pulmonary fibrosis. Front Physiol. 2017;8:777.","journal-title":"Front Physiol"},{"issue":"5","key":"1387_CR76","doi-asserted-by":"publisher","first-page":"H1694","DOI":"10.1152\/ajpheart.00908.2008","volume":"296","author":"I Banerjee","year":"2009","unstructured":"Banerjee I, Fuseler JW, Intwala AR, Baudino TA. IL-6 loss causes ventricular dysfunction, fibrosis, reduced capillary density, and dramatically alters the cell populations of the developing and adult heart. Am J Physiol Heart Circ Physiol. 2009;296(5):H1694\u2013704.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"1387_CR77","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1161\/HYPERTENSIONAHA.109.148635","volume":"56","author":"GC Mel\u00e9ndez","year":"2010","unstructured":"Mel\u00e9ndez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension. 2010;56(2):225\u201331.","journal-title":"Hypertension"},{"issue":"10","key":"1387_CR78","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1172\/JCI13939","volume":"108","author":"H Yasukawa","year":"2001","unstructured":"Yasukawa H, Hoshijima M, Gu Y, Nakamura T, Pradervand S, Hanada T, et al. Suppressor of cytokine signaling-3 is a biomechanical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways. J Clin Invest. 2001;108(10):1459\u201367.","journal-title":"J Clin Invest"},{"issue":"6","key":"1387_CR79","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1161\/01.CIR.0000057545.82749.FF","volume":"107","author":"EK Podewski","year":"2003","unstructured":"Podewski EK, Hilfiker-Kleiner D, Hilfiker A, Morawietz H, Lichtenberg A, Wollert KC, et al. Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy. Circulation. 2003;107(6):798\u2013802.","journal-title":"Circulation"},{"issue":"2","key":"1387_CR80","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.pharmthera.2008.08.002","volume":"120","author":"K Boengler","year":"2008","unstructured":"Boengler K, Hilfiker-Kleiner D, Drexler H, Heusch G, Schulz R. The myocardial JAK\/STAT pathway: from protection to failure. Pharmacol Ther. 2008;120(2):172\u201385.","journal-title":"Pharmacol Ther"},{"issue":"8","key":"1387_CR81","doi-asserted-by":"publisher","first-page":"e10435","DOI":"10.1016\/j.heliyon.2022.e10435","volume":"8","author":"S Duddu","year":"2022","unstructured":"Duddu S, Agrawal M, Chakrabarti R, Ghosh A, Chakravorty N, Tiwari A, et al. Meta-analysis reveals inhibition of the inflammatory cytokine IL-6 affords limited protection post-myocardial ischemia\/infarction. Heliyon. 2022;8(8):e10435.","journal-title":"Heliyon"},{"issue":"3","key":"1387_CR82","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2022.11513","volume":"24","author":"J Wang","year":"2022","unstructured":"Wang J, Wang M, Lu X, Zhang Y, Zeng S, Pan X, et al. IL-6 inhibitors effectively reverse post-infarction cardiac injury and ischemic myocardial remodeling via the TGF-\u03b21\/Smad3 signaling pathway. Exp Ther Med. 2022;24(3):576.","journal-title":"Exp Ther Med"},{"key":"1387_CR83","doi-asserted-by":"publisher","DOI":"10.1172\/JCI163799","author":"C Alter","year":"2023","unstructured":"Alter C, Henseler AS, Owenier C, Hesse J, Ding Z, Lautwein T, et al. IL-6 in the infarcted heart is preferentially formed by fibroblasts and modulated by purinergic signaling. J Clin Invest. 2023. https:\/\/doi.org\/10.1172\/JCI163799.","journal-title":"J Clin Invest"},{"key":"1387_CR84","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.bbrc.2021.02.013","volume":"547","author":"M Zhang","year":"2021","unstructured":"Zhang M, Zhang M, Zhou T, Liu M, Xia N, Gu M, et al. Inhibition of fibroblast IL-6 production by ACKR4 deletion alleviates cardiac remodeling after myocardial infarction. Biochem Biophys Res Commun. 2021;547:139\u201347.","journal-title":"Biochem Biophys Res Commun"},{"key":"1387_CR85","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2021-001869","author":"IM T\u00f8llefsen","year":"2021","unstructured":"T\u00f8llefsen IM, Shetelig C, Seljeflot I, Eritsland J, Hoffmann P, Andersen G. High levels of interleukin-6 are associated with final infarct size and adverse clinical events in patients with STEMI. Open Heart. 2021. https:\/\/doi.org\/10.1136\/openhrt-2021-001869.","journal-title":"Open Heart"},{"issue":"2","key":"1387_CR86","first-page":"113","volume":"11","author":"C Tiller","year":"2022","unstructured":"Tiller C, Reindl M, Holzknecht M, Lechner I, Schwaiger J, Brenner C, et al. Association of plasma interleukin-6 with infarct size, reperfusion injury, and adverse remodelling after ST-elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2022;11(2):113\u201323.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"15","key":"1387_CR87","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jacc.2021.02.049","volume":"77","author":"K Broch","year":"2021","unstructured":"Broch K, Anstensrud AK, Woxholt S, Sharma K, T\u00f8llefsen IM, Bendz B, et al. Randomized trial of Interleukin-6 receptor Inhibition in patients with acute ST-Segment elevation myocardial infarction. J Am Coll Cardiol. 2021;77(15):1845\u201355.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1387_CR88","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jacbts.2021.01.007","volume":"6","author":"P Aukrust","year":"2021","unstructured":"Aukrust P, Kleveland O, Gullestad L. Targeting IL-6 trans-signaling: amplifying the benefits of IL-6 inhibition in myocardial infarction. JACC Basic Transl Sci. 2021;6(5):444\u20136.","journal-title":"JACC Basic Transl Sci"},{"issue":"2","key":"1387_CR89","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s40744-021-00304-0","volume":"8","author":"FS Pierini","year":"2021","unstructured":"Pierini FS, Botta E, Soriano ER, Martin M, Boero L, Mero\u00f1o T, et al. Effect of Tocilizumab on LDL and HDL characteristics in patients with rheumatoid Arthritis. An observational study. Rheumatol Ther. 2021;8(2):803\u201315.","journal-title":"Rheumatol Ther"},{"issue":"21","key":"1387_CR90","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1016\/j.jacc.2025.04.010","volume":"85","author":"F Barkas","year":"2025","unstructured":"Barkas F, Brandts J, De Bacquer D, Jennings C, De Backer GG, Kotseva K, et al. Global variation in Lipoprotein(a) levels among patients with coronary heart disease: insights from the INTERASPIRE study and implications for emerging Lp(a)-Lowering therapies. J Am Coll Cardiol. 2025;85(21):2028\u201342.","journal-title":"J Am Coll Cardiol"},{"key":"1387_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100651","volume":"18","author":"G Reyes-Soffer","year":"2024","unstructured":"Reyes-Soffer G, Yeang C, Michos ED, Boatwright W, Ballantyne CM. High lipoprotein(a): actionable strategies for risk assessment and mitigation. Am J Prev Cardiol. 2024;18:100651.","journal-title":"Am J Prev Cardiol"},{"issue":"5","key":"1387_CR92","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1194\/jlr.P052209","volume":"56","author":"N M\u00fcller","year":"2015","unstructured":"M\u00fcller N, Schulte DM, T\u00fcrk K, Freitag-Wolf S, Hampe J, Zeuner R, et al. IL-6 Blockade by monoclonal antibodies inhibits Apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. J Lipid Res. 2015;56(5):1034\u201342.","journal-title":"J Lipid Res"},{"key":"1387_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.athplu.2023.09.001","volume":"54","author":"A Makris","year":"2023","unstructured":"Makris A, Barkas F, Sfikakis PP, Liberopoulos E, Filippatos TD, Ray KK, et al. Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: is there an association? Atheroscler Plus. 2023;54:1\u20136.","journal-title":"Atheroscler Plus"},{"key":"1387_CR94","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ijcard.2018.06.093","volume":"274","author":"T Ueland","year":"2019","unstructured":"Ueland T, Kleveland O, Michelsen AE, Wiseth R, Dam\u00e5s JK, Holven KB, et al. Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction. Int J Cardiol. 2019;274:348\u201350.","journal-title":"Int J Cardiol"},{"key":"1387_CR95","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.atherosclerosis.2019.07.001","volume":"289","author":"R Yahya","year":"2019","unstructured":"Yahya R, Berk K, Verhoeven A, Bos S, van der Zee L, Touw J, et al. Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight apolipoprotein(a) phenotype. Atherosclerosis. 2019;289:201\u20135.","journal-title":"Atherosclerosis"},{"key":"1387_CR96","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.clnu.2025.02.009","volume":"47","author":"D You","year":"2025","unstructured":"You D, Tang Y, Lange T, Wu Y, Lu M, Shao F, et al. Systematic analysis of relationships between serum lipids with all-cause and cause-specific mortality: evidence from prospective cohort studies of UK biobank and women\u2019s health initiative. Clin Nutr. 2025;47:94\u2013102.","journal-title":"Clin Nutr"},{"issue":"2","key":"1387_CR97","doi-asserted-by":"publisher","first-page":"e000765","DOI":"10.1136\/openhrt-2017-000765","volume":"5","author":"T Ueland","year":"2018","unstructured":"Ueland T, Kleveland O, Michelsen AE, Wiseth R, Dam\u00e5s JK, Aukrust P, et al. Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction. Open Heart. 2018;5(2):e000765.","journal-title":"Open Heart"},{"issue":"4","key":"1387_CR98","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jjcc.2023.05.006","volume":"82","author":"Y Wada","year":"2023","unstructured":"Wada Y, Jensen C, Meyer ASP, Zonoozi AAM, Honda H. Efficacy and safety of interleukin-6 inhibition with Ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): a randomized, double-blind, placebo-controlled, phase 2 trial. J Cardiol. 2023;82(4):279\u201385.","journal-title":"J Cardiol"},{"issue":"2","key":"1387_CR99","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/rth2.12080","volume":"2","author":"RH Olie","year":"2018","unstructured":"Olie RH, van der Meijden PEJ, Ten Cate H. The coagulation system in atherothrombosis: implications for new therapeutic strategies. Res Pract Thromb Haemost. 2018;2(2):188\u201398.","journal-title":"Res Pract Thromb Haemost"},{"key":"1387_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12082883","author":"M Nardin","year":"2023","unstructured":"Nardin M, Verdoia M, Laera N, Cao D, De Luca G. New insights into pathophysiology and new risk factors for ACS. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12082883.","journal-title":"J Clin Med"},{"issue":"6","key":"1387_CR101","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.jacc.2005.03.074","volume":"46","author":"V Fuster","year":"2005","unstructured":"Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol. 2005;46(6):937\u201354.","journal-title":"J Am Coll Cardiol"},{"issue":"7590","key":"1387_CR102","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/bmj.38964.489051.80","volume":"334","author":"PM Rothwell","year":"2007","unstructured":"Rothwell PM. Atherothrombosis and ischaemic stroke. BMJ. 2007;334(7590):379\u201380.","journal-title":"BMJ"},{"issue":"5","key":"1387_CR103","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1055\/s-2000-13202","volume":"26","author":"PL Gross","year":"2000","unstructured":"Gross PL, Aird WC. The endothelium and thrombosis. Semin Thromb Hemost. 2000;26(5):463\u201378.","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"1387_CR104","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2174\/157340308785160570","volume":"4","author":"T Hou","year":"2008","unstructured":"Hou T, Tieu BC, Ray S, Recinos Iii A, Cui R, Tilton RG, et al. Roles of IL-6-gp130 signaling in vascular inflammation. Curr Cardiol Rev. 2008;4(3):179\u201392.","journal-title":"Curr Cardiol Rev"},{"issue":"12","key":"1387_CR105","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1172\/JCI27196","volume":"115","author":"M Gawaz","year":"2005","unstructured":"Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115(12):3378\u201384.","journal-title":"J Clin Invest"},{"issue":"9","key":"1387_CR106","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1182\/blood.V98.9.2720","volume":"98","author":"A Kaser","year":"2001","unstructured":"Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001;98(9):2720\u20135.","journal-title":"Blood"},{"issue":"11","key":"1387_CR107","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/ng.2740","volume":"45","author":"H Helgason","year":"2013","unstructured":"Helgason H, Sulem P, Duvvari MR, Luo H, Thorleifsson G, Stefansson H, et al. A rare nonsynonymous sequence variant in C3 is associated with high risk of age-related macular degeneration. Nat Genet. 2013;45(11):1371\u20134.","journal-title":"Nat Genet"},{"issue":"11","key":"1387_CR108","doi-asserted-by":"publisher","first-page":"766","DOI":"10.3390\/cells14110766","volume":"14","author":"CE Webb","year":"2025","unstructured":"Webb CE, Vautrinot J, Hers I. IL-6 as a mediator of platelet hyper-responsiveness. Cells. 2025;14(11):766.","journal-title":"Cells"},{"issue":"6","key":"1387_CR109","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/00001721-200309000-00001","volume":"14","author":"BS Chin","year":"2003","unstructured":"Chin BS, Conway DS, Chung NA, Blann AD, Gibbs CR, Lip GY. Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: relationship to treatment and prognosis. Blood Coagul Fibrinolysis. 2003;14(6):515\u201321.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"1387_CR110","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1055\/s-0037-1614223","volume":"79","author":"D Stirling","year":"1998","unstructured":"Stirling D, Hannant WA, Ludlam CA. Transcriptional activation of the factor VIII gene in liver cell lines by interleukin-6. Thromb Haemost. 1998;79(1):74\u20138.","journal-title":"Thromb Haemost"},{"key":"1387_CR111","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.125.322533","author":"S Ministrini","year":"2025","unstructured":"Ministrini S, Liberale L, Puspitasari YM, Han J, Kirmes K, Unkelbach LP, et al. Direct interleukin-6 inhibition blunts arterial thrombosis by reducing collagen-mediated platelet activation. Arterioscler Thromb Vasc Biol. 2025. https:\/\/doi.org\/10.1161\/ATVBAHA.125.322533.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"1387_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00963-6","volume":"7","author":"L Huang","year":"2017","unstructured":"Huang L, Zhang Q, Huang X, Qu C, Ma S, Mao Y, et al. Mutation screening in genes known to be responsible for retinitis pigmentosa in 98 small Han Chinese families. Sci Rep. 2017;7(1):1948.","journal-title":"Sci Rep"},{"issue":"10289","key":"1387_CR113","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","volume":"397","author":"PM Ridker","year":"2021","unstructured":"Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, et al. IL-6 Inhibition with Ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10289):2060\u20139.","journal-title":"Lancet"},{"issue":"2","key":"1387_CR114","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1001\/jamacardio.2022.4277","volume":"8","author":"NH Adamstein","year":"2023","unstructured":"Adamstein NH, Cornel JH, Davidson M, Libby P, de Remigis A, Jensen C, et al. Association of Interleukin 6 Inhibition with Ziltivekimab and the Neutrophil-Lymphocyte ratio: A secondary analysis of the RESCUE clinical trial. JAMA Cardiol. 2023;8(2):177\u201381.","journal-title":"JAMA Cardiol"},{"issue":"3","key":"1387_CR115","first-page":"274","volume":"19","author":"L Black","year":"1990","unstructured":"Black L, Coombs VJ, Townsend SN. Reperfusion and reperfusion injury in acute myocardial infarction. Heart Lung. 1990;19(3):274\u201384.","journal-title":"Heart Lung"},{"issue":"19","key":"1387_CR116","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1016\/j.jacc.2021.03.310","volume":"77","author":"PB Parikh","year":"2021","unstructured":"Parikh PB, Bhatt DL, Bhasin V, Anker SD, Skopicki HA, Claessen BE, et al. Impact of percutaneous coronary intervention on outcomes in patients with heart failure: JACC State-of-the-Art review. J Am Coll Cardiol. 2021;77(19):2432\u201347.","journal-title":"J Am Coll Cardiol"},{"issue":"30","key":"1387_CR117","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1093\/eurheartj\/ehw171","volume":"37","author":"O Kleveland","year":"2016","unstructured":"Kleveland O, Kunszt G, Bratlie M, Ueland T, Broch K, Holte E, et al. Effect of a single dose of the interleukin-6 receptor antagonist Tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur Heart J. 2016;37(30):2406\u201313.","journal-title":"Eur Heart J"},{"key":"1387_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2018.04.136","volume":"271","author":"O Kleveland","year":"2018","unstructured":"Kleveland O, Ueland T, Kunszt G, Bratlie M, Yndestad A, Broch K, et al. Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1\u03b2 in non-ST-elevation myocardial infarction. Int J Cardiol. 2018;271:1\u20137.","journal-title":"Int J Cardiol"},{"issue":"9","key":"1387_CR119","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1161\/CIRCULATIONAHA.123.064974","volume":"149","author":"S Prapiadou","year":"2024","unstructured":"Prapiadou S, \u017divkovi\u0107 L, Thorand B, George MJ, van der Laan SW, Malik R, et al. Proteogenomic data integration reveals CXCL10 as a potentially downstream causal mediator for IL-6 signaling on atherosclerosis. Circulation. 2024;149(9):669\u201383.","journal-title":"Circulation"},{"key":"1387_CR120","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02035","volume":"9","author":"HL Orrem","year":"2018","unstructured":"Orrem HL, Nilsson PH, Pischke SE, Kleveland O, Yndestad A, Ekholt K, et al. IL-6 receptor inhibition by tocilizumab attenuated expression of C5a receptor 1 and 2 in non-ST-elevation myocardial infarction. Front Immunol. 2018;9:2035.","journal-title":"Front Immunol"},{"key":"1387_CR121","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-10-45","volume":"10","author":"J van der Pals","year":"2010","unstructured":"van der Pals J, Koul S, Andersson P, G\u00f6tberg M, Ubachs JF, Kanski M, et al. Treatment with the C5a receptor antagonist ADC-1004 reduces myocardial infarction in a porcine ischemia-reperfusion model. BMC Cardiovasc Disord. 2010;10:45.","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"1387_CR122","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cyto.2011.01.007","volume":"54","author":"M Hashizume","year":"2011","unstructured":"Hashizume M, Higuchi Y, Uchiyama Y, Mihara M. IL-6 plays an essential role in neutrophilia under inflammation. Cytokine. 2011;54(1):92\u20139.","journal-title":"Cytokine"},{"key":"1387_CR123","doi-asserted-by":"publisher","first-page":"104013","DOI":"10.1016\/j.ebiom.2022.104013","volume":"80","author":"C Huse","year":"2022","unstructured":"Huse C, Anstensrud AK, Michelsen AE, Ueland T, Broch K, Woxholt S, et al. Interleukin-6 Inhibition in ST-elevation myocardial infarction: immune cell profile in the randomised ASSAIL-MI trial. EBioMedicine. 2022;80:104013.","journal-title":"EBioMedicine"},{"issue":"9","key":"1387_CR124","doi-asserted-by":"publisher","first-page":"101193","DOI":"10.1016\/j.jacadv.2024.101193","volume":"3","author":"KM Kindberg","year":"2024","unstructured":"Kindberg KM, Broch K, Andersen G, Anstensrud AK, \u00c5kra S, Woxholt S, et al. Neutrophil extracellular traps in ST-Segment elevation myocardial infarction: reduced by Tocilizumab and associated with infarct size. JACC Adv. 2024;3(9):101193.","journal-title":"JACC Adv"},{"key":"1387_CR125","doi-asserted-by":"crossref","unstructured":"Huse C, Murphy S, Yang K, Balzer N, Stokke M, Anstensrud AK et al. The effects of interleukin-6-receptor Inhibition on monocytes in STEMI: a substudy of the ASSAIL-MI trial. eBiomedicine. 2025; 121;10596.","DOI":"10.1016\/j.ebiom.2025.105960"},{"key":"1387_CR126","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.3389\/fimmu.2019.02035","volume":"10","author":"TS Kapellos","year":"2019","unstructured":"Kapellos TS, Bonaguro L, Gem\u00fcnd I, Reusch N, Saglam A, Hinkley ER, et al. Human monocyte subsets and phenotypes in major chronic inflammatory diseases. Front Immunol. 2019;10:2035.","journal-title":"Front Immunol"},{"issue":"1","key":"1387_CR127","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41392-021-00569-5","volume":"6","author":"AT He","year":"2021","unstructured":"He AT, Liu J, Li F, Yang BB. Targeting circular RNAs as a therapeutic approach: current strategies and challenges. Signal Transduct Target Ther. 2021;6(1):185.","journal-title":"Signal Transduct Target Ther"},{"key":"1387_CR128","doi-asserted-by":"publisher","first-page":"148114","DOI":"10.1016\/j.brainres.2022.148114","volume":"1797","author":"W Chen","year":"2022","unstructured":"Chen W, Zhang Y, Yin M, Cheng Z, Li D, Luo X, et al. Circular RNA circPRDX3 mediates neuronal survival apoptosis in ischemic stroke by targeting miR-641 and NPR3. Brain Res. 2022;1797:148114.","journal-title":"Brain Res"},{"key":"1387_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2022.114047","volume":"353","author":"R Huang","year":"2022","unstructured":"Huang R, Zhang W, Li W, Gao Y, Zheng D, Bi G. Overexpressing circ_0000831 is sufficient to inhibit neuroinflammation and vertigo in cerebral ischemia through a miR-16-5p-dependent mechanism. Exp Neurol. 2022;353:114047.","journal-title":"Exp Neurol"},{"key":"1387_CR130","doi-asserted-by":"publisher","first-page":"102430","DOI":"10.1016\/j.redox.2022.102430","volume":"56","author":"Q Cheng","year":"2022","unstructured":"Cheng Q, Wang J, Li M, Fang J, Ding H, Meng J, et al. CircSV2b participates in oxidative stress regulation through miR-5107-5p-Foxk1-Akt1 axis in parkinson\u2019s disease. Redox Biol. 2022;56:102430.","journal-title":"Redox Biol"},{"issue":"2","key":"1387_CR131","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.30512","volume":"125","author":"Q Xie","year":"2024","unstructured":"Xie Q, Ma Y, Ren Z, Gu T, Jiang Z. Circular RNA: a new expectation for cardiovascular diseases. J Cell Biochem. 2024;125(2):e30512.","journal-title":"J Cell Biochem"},{"key":"1387_CR132","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25169014","author":"FA Holme","year":"2024","unstructured":"Holme FA, Huse C, Kong XY, Broch K, Gullestad L, Anstensrud AK, et al. Circular RNA profile in atherosclerotic disease: regulation during ST-elevated myocardial infarction. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25169014.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1387_CR133","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.tips.2023.11.002","volume":"45","author":"J Cerneckis","year":"2024","unstructured":"Cerneckis J, Ming GL, Song H, He C, Shi Y. The rise of epitranscriptomics: recent developments and future directions. Trends Pharmacol Sci. 2024;45(1):24\u201338.","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"1387_CR134","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41422-018-0040-8","volume":"28","author":"Y Yang","year":"2018","unstructured":"Yang Y, Hsu PJ, Chen YS, Yang YG. Dynamic transcriptomic m(6)A decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res. 2018;28(6):616\u201324.","journal-title":"Cell Res"},{"key":"1387_CR135","doi-asserted-by":"publisher","first-page":"1532325","DOI":"10.3389\/fimmu.2025.1532325","volume":"16","author":"TB Dahl","year":"2025","unstructured":"Dahl TB, Quiles-Jim\u00e9nez A, Broch K, Anstensrud AK, Gullestad L, Andersen G, et al. The N-6 Methyladenosine dynamics in STEMI and the effect of IL-6 inhibition - a hypothesis generating sub-study of the ASSAIL-MI trial. Front Immunol. 2025;16:1532325.","journal-title":"Front Immunol"},{"key":"1387_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2023.117269","volume":"384","author":"A Rajendran","year":"2023","unstructured":"Rajendran A, Minhas AS, Kazzi B, Varma B, Choi E, Thakkar A, et al. Sex-specific differences in cardiovascular risk factors and implications for cardiovascular disease prevention in women. Atherosclerosis. 2023;384:117269.","journal-title":"Atherosclerosis"},{"issue":"25","key":"1387_CR137","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1016\/j.jacc.2024.04.028","volume":"83","author":"D Vervoort","year":"2024","unstructured":"Vervoort D, Wang R, Li G, Filbey L, Maduka O, Brewer LC, et al. Addressing the global burden of cardiovascular disease in women: JACC State-of-the-Art review. J Am Coll Cardiol. 2024;83(25):2690\u2013707.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1387_CR138","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41577-024-00996-9","volume":"24","author":"KS Forsyth","year":"2024","unstructured":"Forsyth KS, Jiwrajka N, Lovell CD, Toothacre NE, Anguera MC. The connexion between sex and immune responses. Nat Rev Immunol. 2024;24(7):487\u2013502.","journal-title":"Nat Rev Immunol"},{"issue":"5\u20136","key":"1387_CR139","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jpain.2019.11.003","volume":"21","author":"CJ Mun","year":"2020","unstructured":"Mun CJ, Letzen JE, Nance S, Smith MT, Khanuja HS, Sterling RS, et al. Sex Differences in Interleukin-6 Responses Over Time Following Laboratory Pain Testing Among Patients With Knee Osteoarthritis. J Pain. 2020;21(5\u20136):731\u201341.","journal-title":"J Pain"},{"issue":"1","key":"1387_CR140","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56217-x","volume":"16","author":"E Svedlund Eriksson","year":"2025","unstructured":"Svedlund Eriksson E, Lantero Rodriguez M, Halvorsen B, Johansson I, M\u00e5rtensson AKF, Wilhelmson AS, et al. Testosterone exacerbates neutrophilia and cardiac injury in myocardial infarction via actions in bone marrow. Nat Commun. 2025;16(1):1142.","journal-title":"Nat Commun"},{"issue":"1","key":"1387_CR141","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-40744-y","volume":"13","author":"DF Stein","year":"2023","unstructured":"Stein DF, Foley C, Byott M, Nastouli E, Ambler G, Arulkumaran N. Biological sex is associated with heterogeneous responses to IL-6 receptor inhibitor treatment in COVID-19-a retrospective cohort study. Sci Rep. 2023;13(1):13504.","journal-title":"Sci Rep"},{"key":"1387_CR142","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.ejphar.2018.06.028","volume":"833","author":"S Shekhar","year":"2018","unstructured":"Shekhar S, Cunningham MW, Pabbidi MR, Wang S, Booz GW, Fan F. Targeting vascular inflammation in ischemic stroke: recent developments on novel immunomodulatory approaches. Eur J Pharmacol. 2018;833:531\u201344.","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"1387_CR143","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1161\/01.STR.0000089015.51603.CC","volume":"34","author":"PJ Lindsberg","year":"2003","unstructured":"Lindsberg PJ, Grau AJ. Inflammation and infections as risk factors for ischemic stroke. Stroke. 2003;34(10):2518\u201332.","journal-title":"Stroke"},{"issue":"2","key":"1387_CR144","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.atherosclerosis.2010.02.035","volume":"211","author":"AE Michelsen","year":"2010","unstructured":"Michelsen AE, Rathcke CN, Skjelland M, Holm S, Ranheim T, Krohg-S\u00f8rensen K, et al. Increased YKL-40 expression in patients with carotid atherosclerosis. Atherosclerosis. 2010;211(2):589\u201395.","journal-title":"Atherosclerosis"},{"key":"1387_CR145","doi-asserted-by":"publisher","DOI":"10.3390\/life15010047","author":"CI B\u0103cil\u0103","year":"2025","unstructured":"B\u0103cil\u0103 CI, Vl\u0103doiu MG, V\u0103leanu M, Moga DF, Pumnea PM. The role of IL-6 and TNF-Alpha biomarkers in predicting disability outcomes in acute ischemic stroke patients. Life. 2025. https:\/\/doi.org\/10.3390\/life15010047.","journal-title":"Life"},{"key":"1387_CR146","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.2147\/CIA.S258381","volume":"15","author":"H Pawluk","year":"2020","unstructured":"Pawluk H, Grze\u015bk G, Ko\u0142odziejska R, Kozakiewicz M, Wo\u017aniak A, Grzechowiak E, et al. Effect of IL-6 and hsCRP serum levels on functional prognosis in stroke patients undergoing IV-thrombolysis: retrospective analysis. Clin Interv Aging. 2020;15:1295\u2013303.","journal-title":"Clin Interv Aging"},{"issue":"2","key":"1387_CR147","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1161\/CIRCRESAHA.122.320877","volume":"131","author":"J Kamtchum-Tatuene","year":"2022","unstructured":"Kamtchum-Tatuene J, Saba L, Heldner MR, Poorthuis MHF, de Borst GJ, Rundek T, et al. Interleukin-6 predicts carotid plaque severity, vulnerability, and progression. Circ Res. 2022;131(2):e22\u201333.","journal-title":"Circ Res"},{"issue":"1","key":"1387_CR148","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12974-025-03365-y","volume":"22","author":"C Hall","year":"2025","unstructured":"Hall C, Nguyen DT, Mendoza K, Tan C, Chauhan A. Inhibition of IL-6 trans-signaling promotes post-stroke functional recovery in a sex and dose-dependent manner. J Neuroinflammation. 2025;22(1):52.","journal-title":"J Neuroinflammation"},{"key":"1387_CR149","doi-asserted-by":"publisher","DOI":"10.1136\/svn-2024-003574","author":"X Chu","year":"2024","unstructured":"Chu X, Ma Z, Liu Y, Sun J, Wang N, Li C, et al. IRIS, a randomised, double-blind, placebo-controlled trial of interleukin-6 receptor inhibition undergoing endovascular treatment in acute anterior circulation ischaemic stroke: study rationale and design. Stroke Vasc Neurol. 2024. https:\/\/doi.org\/10.1136\/svn-2024-003574.","journal-title":"Stroke Vasc Neurol"},{"issue":"4","key":"1387_CR150","doi-asserted-by":"publisher","first-page":"172","DOI":"10.4103\/bc.bc_52_22","volume":"8","author":"F Eren","year":"2022","unstructured":"Eren F, Yilmaz SE. Neuroprotective approach in acute ischemic stroke: a systematic review of clinical and experimental studies. Brain Circ. 2022;8(4):172\u20139.","journal-title":"Brain Circ"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01387-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-025-01387-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01387-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T09:02:00Z","timestamp":1768554120000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-025-01387-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":150,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1387"],"URL":"https:\/\/doi.org\/10.1007\/s11883-025-01387-8","relation":{},"ISSN":["1534-6242"],"issn-type":[{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animal or human subjects were used in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"There are no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"13"}}